Cargando…

Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost

PURPOSE: Patient satisfaction is important in the treatment of glaucoma. Suboptimal compliance and impaired long-term outcome are a likely result of poor tolerability. The present multicentre, international, transverse, epidemiological survey was conducted to assess the satisfaction of patients who...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erb, Carl, Stalmans, Ingeborg, Iliev, Milko, Muñoz-Negrete, Francisco José
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936704/ https://www.ncbi.nlm.nih.gov/pubmed/33688161 http://dx.doi.org/10.2147/OPTH.S295821

Ejemplares similares

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction
por: Muñoz Negrete, Francisco José, et al.
Publicado: (2017)

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction
por: Beck, Daniel Edward Robert, et al.
Publicado: (2017)

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction [Corrigendum]
Publicado: (2017)

Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost
por: García-Feijoo, Julian, et al.
Publicado: (2016)

Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
por: Harasymowycz, Paul, et al.
Publicado: (2021)

Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study
por: Economou, Mario A, et al.
Publicado: (2018)

Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study
por: Esaki, Yoshihiko, et al.
Publicado: (2016)

The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
por: Misiuk-Hojlo, Marta, et al.
Publicado: (2018)

Comparison of the Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost
por: Kim, Joon Mo, et al.
Publicado: (2021)

Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost
por: Tokuda, Naoto, et al.
Publicado: (2017)

Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost
por: Imasawa, Mitsuhiro, et al.
Publicado: (2016)

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
por: Uusitalo, Hannu, et al.
Publicado: (2016)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
por: Sacchi, Matteo, et al.
Publicado: (2014)

Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-angle Glaucoma
por: Seong, Hyo Jin, et al.
Publicado: (2021)

Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost
por: Maruyama, Yuko, et al.
Publicado: (2015)

Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination
por: Inoue, Kenji, et al.
Publicado: (2020)

Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial
por: Kim, Dai Woo, et al.
Publicado: (2021)

Tolerability in Glaucoma Patients Switched from Preserved to Preservative-Free Prostaglandin-Timolol Combination: A Prospective Real-Life Study
por: Jandroković, Sonja, et al.
Publicado: (2022)

Crossover randomized study comparing the efficacy and tolerability of preservative-free Tafluprost 0.0015% to Latanoprost 0.005% in patients with primary open-angle glaucoma
por: Hagras, Sherein M, et al.
Publicado: (2021)

European real-world data about the use of a new delivery system containing a preservative-free multi-dose glaucoma treatment
por: Denis, Philippe, et al.
Publicado: (2020)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
por: Katz, Gregory, et al.
Publicado: (2010)

Cystoid macular edema associated with preservative-free latanoprost after uncomplicated cataract surgery: case report and review of the literature
por: Makri, Olga E., et al.
Publicado: (2017)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
por: Inoue, Kenji, et al.
Publicado: (2012)

Latanoprost in the treatment of glaucoma
por: Alm, Albert
Publicado: (2014)

24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy
por: Konstas, Anastasios-Georgios, et al.
Publicado: (2016)

Correction to: 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy
por: Konstas, Anastasios-Georgios, et al.
Publicado: (2020)

Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study
por: Gutierrez-Diaz, Esperanza, et al.
Publicado: (2014)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Miyashiro, Michael J, et al.
Publicado: (2010)

Impact of benzalkonium chloride-preserved and preservative-free latanoprost eye drops on cultured human conjunctival goblet cells upon acute exposure and differences in physicochemical properties of the eye drops
por: Müllertz, Olivia, et al.
Publicado: (2021)

Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial
por: Bacharach, Jason, et al.
Publicado: (2023)

Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride
por: Liang, H, et al.
Publicado: (2008)

Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system
por: Ryan, Gerard, et al.
Publicado: (2011)

Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial [Corrigendum]
Publicado: (2023)

An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (w/v) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival
por: Freiberg, Josefine C., et al.
Publicado: (2022)

Influence of Latanoprost on Retinal Microcirculation in Glaucoma
por: Kremmer, S, et al.
Publicado: (2014)

Prostaglandin-associated periorbitopathy in latanoprost users
por: Nakakura, Shunsuke, et al.
Publicado: (2014)

Latanoprost could exacerbate the progression of presbyopia
por: Ayaki, Masahiko, et al.
Publicado: (2019)

Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis
por: Lee, Jong-Wook, et al.
Publicado: (2022)

Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma
por: Walimbe, Tejaswini, et al.
Publicado: (2016)

Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in France
por: Lazzaro, Carlo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gkr72r9e6kae1vale9i7astj41